drugset / Trial / NCT00976391

A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine

NCT00976391

Phase 3 Completed 586 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.

Timeline

Start
2009-09
Primary completion
2011-10
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic
Comparator albiglutide Peptide 50 mg Subcutaneous
Comparator insulin glargine Protein / enzyme biologic